CGTX Stock Price | Cognition Therapeutics Inc P/E, Revenue, EPS, & Forecasts

Cognition Therapeutics Inc • CGTX

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Cognition Therapeutics Inc

Ticker

CGTX

Trading on

NASDAQ

ISIN

US19243B1026

Industry

Biotechnology

Sector

Healthcare

CEO

Lisa Ricciardi

Headquarters

2500 Westchester Ave., Purchase, NY, United States, 10577

Employees

Website

cogrx.com

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.

Metrics

BasicAdvanced

Market cap

$98.9M

P/E ratio

EPS

-$0.47

Dividend Yield

0.00%

Beta

1.25

Forward P/E ratio

EBIDTA

$-44.8M

Ex dividend date

Price & volume

Market cap

$98.9M

Average daily volume

0.7M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

Price to book

2.72

Earnings

EPS

-$0.47

EPS estimate (current quarter)

-$0.09

EPS estimate (next quarter)

-$0.08

EBITDA

$-44.8M

Revenues (TTM)

$0M

Revenues per share (TTM)

$0.00

Technicals

Beta

1.25

52-week High

$3.83

52-week Low

$0.22

50-day moving average

$1.23

200-day moving average

$1.27

Short ratio

8.07

Short %

9.00%

Management effectiveness

ROE (TTM)

-109.73%

ROA (TTM)

-78.99%

Profit margin

0.00%

Gross profit margin

$0M

Operating margin

0.00%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

0.00%

Share stats

Outstanding Shares

88.3M

Float

81.5M

Insiders %

2.26%

Institutions %

23.86%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 4 analysts.

Average price target

$3.50

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.19

-$0.17

-11.00%

Q4 • 24Missed

-$0.14

-$0.25

44.00%

Q1 • 25Beat

-$0.11

Q2 • 25Beat

-$0.06

-$0.10

40.00%

Q3 • 25Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0M

$-6.7M

-∞%

Q2 • 25

$0M

$-4.9M

-∞%

Q3 • 25

NaN%

-26.79%

NaN%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$19.6M

$12.6M

64.18%

Q2 • 25

$43.4M

$6.9M

15.82%

Q3 • 25

121.15%

-45.48%

-75.35%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-5.6M

$0M

$0.8M

$-5.6M

Q2 • 25

$-5.7M

$0M

$33.9M

$-5.7M

Q3 • 25

0.50%

4,410.24%

0.50%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Cognition Therapeutics Inc share?

Cognition Therapeutics Inc shares are currently traded for undefined per share.

How many shares does Cognition Therapeutics Inc have?

Cognition Therapeutics Inc currently has 88.3M shares.

Does Cognition Therapeutics Inc pay dividends?

No, Cognition Therapeutics Inc doesn't pay dividends.

What is Cognition Therapeutics Inc 52 week high?

Cognition Therapeutics Inc 52 week high is $3.83.

What is Cognition Therapeutics Inc 52 week low?

Cognition Therapeutics Inc 52 week low is $0.22.

What is the 200-day moving average of Cognition Therapeutics Inc?

Cognition Therapeutics Inc 200-day moving average is $1.27.

Who is Cognition Therapeutics Inc CEO?

The CEO of Cognition Therapeutics Inc is Lisa Ricciardi.

How many employees Cognition Therapeutics Inc has?

Cognition Therapeutics Inc has 25 employees.

What is the market cap of Cognition Therapeutics Inc?

The market cap of Cognition Therapeutics Inc is $98.9M.

What is the P/E of Cognition Therapeutics Inc?

The current P/E of Cognition Therapeutics Inc is null.

What is the EPS of Cognition Therapeutics Inc?

The EPS of Cognition Therapeutics Inc is -$0.47.

What is the PEG Ratio of Cognition Therapeutics Inc?

The PEG Ratio of Cognition Therapeutics Inc is null.

What do analysts say about Cognition Therapeutics Inc?

According to the analysts Cognition Therapeutics Inc is considered a buy.